Results of the Estimation of Biosimilarity of RinLiz^® (LLC «GEROPHARM», Russia) and Humalog^® (Lilly France, France) Using the Method of the Hyperinsulinemic Eulygemic Clamp on Healthy Voluntary

Introduction. Insulin is the most effective hypoglycemic agent currently used in the clinical practice. Compared with recombinant human insulin, insulin lispro have a blood glucose profile that is much closer to physiological. The clinical trials program of insulin bioassays includes pharmacology studies: pharmacokinetics (PK), pharmacodynamics (PD), and a clinical safety study.

Aim. To compare PK and PD of RinLiz® U100, solution for intravenous and subcutaneous administration (LLC «GEROFARM», Russia) and Humalog® U100, solution for intravenous and subcutaneous administration (Lilly France, France) in hyperinsulinemic euglycemic clamp.

Materials and methods. This was randomized double-blind, two-arm crossover study in 28 healthy volunteers (NCT03604575). The studied preparations were injected before the clamp with a dose of 0.3 U/kg once subcutaneously in the area of subcutaneous fat in the anterior abdominal wall. During the study, regular blood sampling was performed; the amount of insulin lispro was determined by ELISA in the samples. The results of the determination were used to calculate the PK parameters and construct the curves «concentration – time». Based on the measurement of glycemia, the glucose infusion rate was adjusted. These data were used to calculate the PD parameters. The comparability of the studied drugs was considered proven if 90 % confidence intervals (CI) for the ratio of geometric mean PK parameters C_ins. max and AUC_ins. 0-8 and 95 % CI for the ratio of geometric mean PD parameters GIR_max and AUC_GIR0-8,5 were in the range of 80–125 %. Statistical data processing and presentation of the results was carried out using software packages R 3.4.2.

Results and discussion. In the course of CI comparative PK and PD of RinLiz® and Humalog®, it was revealed that they have comparable PK and PD profiles. The CI for the logarithmically converted ratios of the values of the PK parameters was C_ins. max 85.99–96.85 % and AUC_ins. 0-8 90.58–97.28 %, the PD of the parameters were 95.64–118.94 for GIR_max and 96.5–121.36 for AUC_GIR0-8.5, all the CIs correspond to the set the boundaries of 80–125 % to establish comparability between RinLiz® and the original drug.

Conclusion. The results demonstrated the high degree of similarity of RinLiz® U100 and Humalog® U100 in terms of PK, PD profiles and safety.

1. Campbell R. K., Campbell L. K., White J. R., Insulin lispro: its role in the treatment of diabetes mellitus. Ann Pharmacother. 1996; 30(11): 1263–1271.

2. White J. R., Campbell R. K., Hirsch I. Insulin analogues: new agents for improving glycemic control. Postgrad Med. 1997; 101(2): 58–70.

3. DeFronzo R. A., Tobin J. D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237(3): E214–E223.

4. Heinemann L., Anderson J. H. Measurement of insulin absorption and insulin action. Diabetes Technol Ther. 2004; 6(5): 698–718.

5. Heinemann L. Overcoming obstacles: new management options. Eur J Endocrinol. 2004; 151: T23–Т30.

6. Roden M. Blocking Fatty Acids’ Mystery Tour: A Therapy for Metabolic Syndrome? Cell Metabolism. 2007: 89–91.

7. Federal Law No. 61 «On the Circulation of Medicines» dated April 12, 2010 (as amended on December 29, 2015). Available at: http://www.pravo.gov.ru (in Russ.).

8. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues// 26 February 2015, EMEA/CHMP/ BMWP/32775/2005_Rev. 1.

9. Guideline on similar biological medicinal products (CHMP/437/04 Rev. 1).

10. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev. 1).

11. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins (EMEA/CHMP/ 89249/2004).

12. Guideline on the investigation of bioequivalence (CPMP/EWP/ QWP/1401/98).

13. Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins (EMEA/CHMP/BMWP/14327/2006).

14. Decision No. 89 of November 3, 2016 «On approval of the rules for conducting research on biological drugs of the Eurasian Economic Union», chapter 15.7 «Preclinical and clinical development of bioanalogous (biosimilar) drugs containing recombinant insulin and insulin analogues» (in Russ.).

15. Development of bio-analogous (biosimilar) medicines containing human engineering insulin or analogues of human insulin as a pharmaceutical substance // Guidelines for the Expertise of Medicines. Volume IV – M.: Polygraph-plus. 2014: 172. Chapter 3. «Development of bio-analogous (biosimilar) drugs containing, as a pharmaceutical substance, genetically engineered human insulin or analogues of human insulin» (in Russ.).

16. Rabiee A., Magruder J. T., Grant C., Salas-Carrillo R., Gillette A., DuBois J., Shannon R. P., Andersen D. K., Elahi D. Accuracy and reliability of the Nova StatStrip® glucose meter for real-time blood glucose determinations during glucose clamp studies. J Diabetes Sci Technol. 2010; 4(5): 1195–11201.

17. Lindquist K. A., Chow K., West A., Pyle L., Isbell T. S., Cree-Green M., Nadeau K. J. The StatStrip Glucose Monitor Is Suitable for Use During Hyperinsulinemic Euglycemic Clamps in a Pediatric Population. Diabetes Technol Ther. 2014; 16(5):298–302.

18. Linnebjerg H., Lam E. C., Seger M.E., Coutant D., Chua L., Chong C. L., Ferreira M. M., Soon D., Zhang X. Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies. Diabetes Care. 2015; 38: 2226–2233.

19. Heise T., Zijlstra E., Nosek L., Heckermann S., Plum-Mörschel L., Forst T. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes, Obesity and Metabolism. 2016; 18(10): 962–972. Doi: 10.1111/dom.12703. Epub 2016 Jul 13.

20. Singh B., Saxena A. Surrogate markers of insulin resistance. World J Diabetes. 2010; 1(2): 36–47.